Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Orion Biotechnology

Request full access

A clinical stage biotechnology company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases

Ottawa, CanadaFounded 2017Biotech & Life Sciences

About Orion Biotechnology

Orion Biotechnology is a pioneering company in the field of drug discovery and development, specializing in G Protein Coupled Receptor (GPCR) targeted therapies. The company focuses on creating treatments for metabolic and immunological diseases through precision engineering of small protein ligands that target GPCRs. Orion's innovative approach is supported by one of the fastest drug discovery platforms in the industry, offering a significant opportunity to develop a new generation of GPCR-targeted medicines. The company's lead compound, OB 002, is a GPCR analog of CCL5, demonstrating best-in-class potency and a proven mechanism of action. This compound has broad applicability across a range of serious diseases, including cancer, infectious diseases, and neuroinflammatory disorders.

Orion Biotechnology serves clients in the biopharmaceutical sector, particularly those focused on oncology, immunology, and other serious diseases. The company operates in the global healthcare market, leveraging its advanced drug discovery platform to develop high-value GPCR-targeted therapies. Orion's business model revolves around the discovery, development, and commercialization of these therapies, generating revenue through partnerships, licensing agreements, and direct sales of its proprietary compounds.

The company is led by a highly experienced team with world-leading expertise in GPCR pharmacology and peptide protein engineering. Orion Biotechnology is committed to advancing a diversified pipeline of potential antagonist and agonist therapies, aiming to unlock the therapeutic potential of previously undruggable GPCRs.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
68.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Jul 2024 $743K $3M Undisclosed ↗
SERIES AEquity / VC Mar 2023 $0 — Undisclosed —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Orion Biotechnology website traffic

Latest recorded traffic for Orion Biotechnology is 2.2K monthly website visits, up 233.3% over the last three months. Orion Biotechnology's team declined 5.3% over the past year.

Latest monthly visits2.2K 3-month web change+233.3% 1-year team growth-5.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Engimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies Allschwil, Switzerland Operational 12 $15M $57M
Stratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases Natick, United States Operational
Nabla BioDeveloping AI and wet-lab technologies to enable the rational design of selective, functional drugs targeting previously undruggable sites Cambridge, United States Operational
Nereid TherapeuticsA pioneer of the biomolecular condensate field and one of the world’s leading experts in intracellular liquid-liquid phase separation Boston, United States Operational
Aperiam BioTaking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry New York City, United States Operational
PRAMOMOLECULARDeveloping innovative self-delivering siRNAs to silence the formation of disease-causing proteins to improve the treatment of lung and pancreatic cancer Berlin, Germany Operational
Juvena TherapeuticsA biopharmaceutical platform which is discovering novel protein-based therapeutics Palo Alto, United States Operational
FimecsTargeted protein degradation therapeutics for undruggable diseases Fujisawa, Japan Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Orion Biotechnology in the Ottawa ecosystem

Live from Dealroom

The Orion Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • The National Centre for Research and Development

Series A2 investors entered at this stage

  • Keiretsu Forum
  • HaloHealth

Other known investors5 additional known investors

  • University of Geneva
  • Cantilever Business Partners
  • EPFL Innovation Park
  • Globivest
  • KYTO Technology & Life Science
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States30%
🇨🇦 Canada30%
🇲🇹 Malta10%
🇮🇳 India10%
🇵🇱 Poland10%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Orion Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Orion Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.